Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $78.94 USD
Change Today -0.38 / -0.48%
Volume 1.3M
DVA On Other Exchanges
Symbol
Exchange
New York
As of 8:04 PM 07/2/15 All times are local (Market data is delayed by at least 15 minutes).

davita healthcare partners i (DVA) Key Developments

DaVita HealthCare Partners Inc. Appoints George Hong as National Medical Director for Healthcare Partners

DaVita HealthCare Partners Inc. announced George Hong, M.D. will serve as a national medical director for HealthCare Partners supporting a variety of national initiatives including Accountable Care Organizations (ACOs). Most recently, Dr. Hong was a lead medical director for Regal Medical Group.

DaVita HealthCare Partners Inc. Appoints Paul Lim as National Medical Director

DaVita HealthCare Partners Inc. announced Paul Lim, M.D., will serve as a national medical director supporting HealthCare Partners' national clinical initiatives, including medical management, care transitions and utilization management. Most recently, Dr. Lim served as chief medical officer at Prospect Medical Group where he oversaw medical management, performance programs and the pharmacy departments for its independent physician associations (IPAs).

DaVita Kidney Care Announcement Regarding Atlanta Lawsuit

DaVita Kidney Care announced the next step in an agreement in principle for a settlement in an Atlanta-based case, which previously was announced on April 15. The lawsuit was brought by private attorneys regarding allegations of medication wastage from 2003 to 2010.

DaVita HealthCare Partners Inc. Reports Consolidated Unaudited Earnings Results for First Quarter Ended March 31, 2015; Revised Earnings Guidance for 2015

DaVita HealthCare Partners Inc. reported consolidated unaudited earnings results for first quarter ended March 31, 2015. For the quarter, the company reported total net revenues of $3,287,965,000 compared with $3,042,776,000 for the same period last year. Operating loss was $64,156,000 compared with operating income of $441,225,000 for the same period last year. Loss before income taxes was $162,081,000 compared with income before income taxes of $336,588,000 for the same period last year. Net loss attributable to DaVita HealthCare Partners Inc. was $110,617,000 or $0.52 diluted per share compared with net income attributable to DaVita HealthCare Partners Inc. of $183,289,000 or $0.85 diluted per share for the same period last year. Net cash provided by operating activities was $410,089,000 compared with $419,107,000 for the same period last year. Additions of property and equipment was $121,421,000 compared with $126,562,000 for the same period last year. Adjusted operating income excluding an accrual of an estimated loss contingency was $431,000 compared with $441,000 for the same period last year. Adjusted net income attributable to DaVita HealthCare Partners Inc. excluding an accrual of an estimated loss contingency was $187,000 or $0.86 diluted per share compared with $183,000 or $0.85 diluted per share for the same period last year. Net debt, net of cash and cash equivalents was $7,502,000 compared with $7,555,000 for the same period last year. The company is updating its consolidated operating income for 2015 to now be in the range of $1.800 billion to $1.925 billion. Previous consolidated operating income guidance for 2015 was in the range of $1.750 billion to $1.900 billion. Consolidated operating cash flow for 2015 to be in the range of $1.500 billion to $1.700 billion. 2015 effective tax rate attributable to DaVita HealthCare Partners Inc. to now be approximately 39.0% to 40.0% previous the company expected 2015 effective tax rate attributable to DaVita HealthCare Partners Inc. was 39.5% to 40.5%.

Kidney Care Reports Unaudited Earnings Results for First Quarter Ended March 31, 2015; Revised Earnings Guidance for 2015

Kidney Care reported unaudited earnings results for first quarter ended March 31, 2015. For the quarter, the company reported total net revenues of $2,360 million compared with $2,202 million for the same period last year. Operating loss was $124 million compared with operating income of $387 million for the same period last year. The company is updating operating income for Kidney Care for 2015 to now be in the range of $1.575 billion to $1.650 billion. Previous operating income guidance for Kidney Care for 2015 was in the range of $1.525 billion to $1.625 billion.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
DVA:US $78.94 USD -0.38

DVA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Apollo Medical Holdings Inc $6.25 USD -0.65
Fresenius Medical Care AG & Co KGaA €73.91 EUR -0.361
Fresenius SE & Co KGaA €58.11 EUR +0.439
IPC Healthcare Inc $56.53 USD +0.49
Team Health Holdings Inc $65.86 USD -0.20
View Industry Companies
 

Industry Analysis

DVA

Industry Average

Valuation DVA Industry Range
Price/Earnings 39.8x
Price/Sales 1.3x
Price/Book 3.4x
Price/Cash Flow 16.5x
TEV/Sales 0.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact DAVITA HEALTHCARE PARTNERS I, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.